Bone morphogenetic protein receptor type-2 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Bone morphogenetic protein receptor type-2 shows approved-linked disease relevance led by bone disease. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q13873. Start with bone disease, then reuse UniProt Q13873 as the stable protein anchor across project notes and exports.
Start with bone disease, then reuse UniProt Q13873 as the stable protein anchor across project notes and exports.
Bone morphogenetic protein receptor type-2 shows approved-linked disease relevance led by bone disease. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with bone disease because it currently carries approved-linked support. Linked drugs include DIBOTERMIN ALFA, EPTOTERMIN ALFA. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyBone morphogenetic protein receptor type-2
Review this target as Bone morphogenetic protein receptor type-2, mapped to UniProt Q13873. Sequence length is 1038 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Bone morphogenetic protein receptor type-2 as ChEMBL target CHEMBL5467, mapped to UniProt Q13873. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Bone morphogenetic protein receptor type-2 is the right protein anchor across sources, using UniProt Q13873 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why bone disease is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Bone morphogenetic protein receptor type-2 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q13873 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Bone morphogenetic protein receptor type-2 |
| UniProt Accession | Q13873 |
| Component Type | Protein |
| Sequence Length | 1038 aa |
Bone morphogenetic protein receptor type-2
Review this target as Bone morphogenetic protein receptor type-2, mapped to UniProt Q13873. Sequence length is 1038 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Bone morphogenetic protein receptor type-2 shows approved-linked disease relevance led by bone disease. 5 more disease programs remain visible in the same review block.
Start review with bone disease because it currently carries approved-linked support. Linked drugs include DIBOTERMIN ALFA, EPTOTERMIN ALFA. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL400402 | 8.52 | Kd | 3.0 | Preclinical |
| CHEMBL5404016 | 8.3 | Ki | 5.0 | Preclinical |
| CHEMBL5404269 | 8.21 | Ki | 6.2 | Preclinical |
| CHEMBL5422418 | 8.15 | Ki | 7.0 | Preclinical |
| CHEMBL5434353 | 8.1 | Ki | 8.0 | Preclinical |
| CHEMBL4289017 | 8.1 | Kd | 8.0 | Preclinical |
| CHEMBL5653589 | 7.83 | Kd | 14.69 | Preclinical |
| CHEMBL2385579 | 7.8 | IC50 | 15.9 | Preclinical |
| CHEMBL5420022 | 7.8 | Ki | 16.0 | Preclinical |
| CHEMBL5437902 | 7.75 | Ki | 18.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 125 | 38 | 6.2 |
| assay format | 26 | 19 | 7.0 |
| cell-based format | 6 | 0 | — |
| subcellular format | 5 | 11 | 6.5 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 1 | 1 | 6.7 |